Cloud-Clone launches full-lineage multi-species primary neural cell portfolio

Cloud-Clone Corp. unveiled a multi-species primary neural cell portfolio covering ten species and multiple neural cell types to support neuroscience, drug screening and regenerative medicine research. The launch targets a major translational gap in CNS R&D, where most drug candidates that succeed in animals fail in human trials.

Why it matters: - The launch is aimed at one of neuroscience’s biggest problems: animal models often do not predict human outcomes well enough for central nervous system drug development. - Cloud-Clone is positioning the portfolio as a research supply base for translational neuroscience, drug screening, blood-brain barrier testing and cell therapy work. - The company says the new offering is designed to support both academic research and pharmaceutical development as demand for primary neural cells grows.

What happened: - Cloud-Clone Corp. announced a full-lineage multi-species primary neural cell portfolio covering ten species. - The portfolio includes neurons, glial cells and accessory neural functional cells. - The company said the launch expands its primary cell business for neuroscience and regenerative medicine research. - The announcement was dated Aug. 17, 2026, in Houston.

The details: - Cloud-Clone says its biobank covers more than 10 species, including humans, mice, rats, rabbits, dogs, pigs, sheep, cats, guinea pigs and chickens. - The company says it has more than 560 ready-to-use primary cell products and more than 3,000 cell stock lines. - The neural lineup includes trigeminal ganglion neurons, hippocampal neurons, olfactory bulb neurons, cerebellar granule neurons, cerebral cortical neurons, dorsal root ganglion neurons, spinal cord neurons and retinal ganglion neurons. - Stable bulk shipments are already established for trigeminal ganglion neurons, retinal ganglion cells, cerebral cortical neurons and dorsal root ganglion cells. - Cloud-Clone says these neuron types are used in screening for analgesics, glaucoma treatments, stroke therapeutics and Alzheimer’s disease research. - The glial portfolio includes Schwann cells, cerebral astrocytes, retinal Müller cells, oligodendrocyte precursor cells, microglia, spinal astrocytes and olfactory bulb astrocytes. - Schwann cells are used in peripheral nerve regeneration and nerve injury repair. - Microglia are used in neuroinflammation research and anti-inflammatory drug screening. - Cerebral astrocytes are used in blood-brain barrier maintenance, neuroinflammation research and stroke studies. - The accessory cell library includes peripheral fibroblasts, meningeal cells, brain microvascular endothelial cells, choroid plexus fibroblasts, cerebral vascular pericytes and neural stem/progenitor cells. - Brain microvascular endothelial cells are supplied for blood-brain barrier permeability testing. - The company says co-culture systems can be built to model the neurovascular unit in vitro. - Cloud-Clone says its products support single-cell assays, co-culture models, 3D neural organoid construction and preclinical transplantation studies. - The company says its quality control includes in-house tissue sampling in SPF-grade animal facilities and biomarker testing using NeuN, GFAP and Iba1. - Cloud-Clone says it provides full test reports covering cell viability, purity and microbial detection. - The company says it offers international cold-chain shipping, English certificates of analysis, customized OEM packaging and matched complete culture media. - Cloud-Clone says a dedicated neural cell specialist team provides culture protocols and troubleshooting support. - Contact details listed in the release include the company website, LinkedIn, Instagram, TikTok and X profiles, plus phone numbers and email addresses.

Between the lines: - Cloud-Clone is emphasizing scale, species breadth and large-animal coverage because many suppliers focus mainly on mouse and rat neural cells. - The company is also framing the launch as a supply-chain play, not just a product update, by highlighting logistics, quality control and export infrastructure. - The release leans hard on translational medicine language, suggesting Cloud-Clone wants to be seen as a core materials supplier for work that can move from bench to clinic.

What's next: - Cloud-Clone expects academic and pharmaceutical screening orders to keep growing in the near term. - The company says longer-term demand should rise as cell therapy and tissue engineering move further into clinical translation. - Cloud-Clone says it will continue building an integrated raw materials platform for global neuroscience and regenerative medicine research.

The bottom line: - Cloud-Clone is betting that full-lineage, multi-species neural cell supply can make it a bigger player in the fast-growing market for translational neuroscience and regenerative medicine tools.